First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci188492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Fernanda I Staquicini und 13 weiteren Autor:innen. Beteiligte Einrichtung: MBrace Therapeutics, San Diego, California, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Receptor, EphA5, Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MBrace Therapeutics.
Abstract (Originalsprache)
Contemporary cancer treatment strategies are shifting toward targeted therapies to improve efficacy and minimize toxicity. Here, we report the design and preclinical evaluation of MBRC-101, a first-in-class antibody-drug conjugate (ADC) targeting EphA5, a receptor tyrosine kinase with an established role in embryonic development but not extensively studied in cancer. We show that EphA5 is expressed in multiple solid tumors, including cancers of the aerodigestive (non-small cell lung, head and neck, gastric, colon, and pancreatic) and genitourinary (bladder and ovary) tracts, as well as most breast cancer subsets (including triple-negative tumors), with limited expression in normal tissues. MBRC-101 is a humanized anti-EphA5 antibody conjugated to monomethyl auristatin E (MMAE) through a ThioBridge, thereby ensuring stable drug-to-antibody ratio and reducing off-target effects. MBRC-101 showed potent antitumor activity, achieving complete tumor regression in several patient-derived xenograft models. Preclinical Good Laboratory Practice-compliant toxicology studies in rats and nonhuman primates demonstrated that MBRC-101 is well tolerated, with observed toxicities limited to known MMAE off-target effects. These findings establish EphA5 as a therapeutic target in cancer and support the translational development of MBRC-101 as a promising ADC candidate for clinical evaluation, currently in a first-in-human multicenter investigational trial for patients with advanced solid tumors (ClinicalTrials.gov, NCT06014658).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MBrace Therapeutics, San Diego, California, USA.
- Rutgers Cancer Institute, Newark, New Jersey, USA.
- Division of Cancer Biology, Department of Radiation Oncology, and.
- Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Förderung
- MBrace Therapeutics
Zitieren
APA
Staquicini, F. I., Tang, F. H., de Oliveira, V., Kim, S. Y., Chen, E. R., Markosian, C., Staquicini, D. I., Wu, Y., Parsons, J. K., Barnhart, K. F., Alley, S. C., Chen, I., Arap, W., & Pasqualini, R. (2025). First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors. Journal of Clinical Investigation. https://doi.org/10.1172/jci188492
Vancouver
Staquicini FI, Tang FH, de Oliveira V, Kim SY, Chen ER, Markosian C, et al. First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors. Journal of Clinical Investigation. 2025. doi:10.1172/jci188492
BibTeX
@article{Staquicini2025,
author = {Staquicini, Fernanda I and Tang, Fenny Hf and de Oliveira, Vanessa and Kim, Sun-Young and Chen, Ethan R and Markosian, Christopher and Staquicini, Daniela I and Wu, Yongjian and Parsons, J Kellogg and Barnhart, Kirstin F and Alley, Stephen C and Chen, Isan and Arap, Wadih and Pasqualini, Renata},
title = {First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci188492}
}
EUVIMED